Showing results (171-180 of 259) with videos related to
Sort By:
Pageof 26
Investigational New Drugs|November 26, 2013
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumorsSharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2024
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLCJhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2023
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical TrialEdward B Garon, Shun Lu, Yasushi Goto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2018
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung CancerYi-Long Wu, Li Zhang, Dong-Wan Kim, et al.Clinical and Translational Medicine|December 23, 2024
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysisShang-Gin Wu, Chao-Chi Ho, James Chih-Hsin Yang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global StudySai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2020
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLCMark M Awad, Shirish M Gadgeel, Hossein Borghaei, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 30, 2023
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJames Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, et al.Pageof 26